More importantly, serum IL-1β levels appear to correlate with disease activity, as evidenced by the fact that compared to the serum IL-1β levels of NEC patients in clinical stages I and II, those of patients in stage III have increased further. This evidence concerns the gene IL1B and necrotizing enterocolitis.